0652: Serum from Patients with SLE and Anti-MDA5 Antibody-Positive Dermatomyositis Induce Shared Monocyte Cytokine Signature Through Type 1 Interferon Pathway

Shohei Nakamura, Yuko okamoto, Yasuhiro Katsumata and Masayoshi Harigai, Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

Background/Purpose: Although type 1 interferon (IFN) plays a pivotal role in the pathogenesis of systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM) [1] as typically evidenced by elevated expression of type 1 IFN-stimulated genes (ISGs) in peripheral immune cells, contribution of serum factors to ISGs was not fully elucidated. We investigated the cytokine induction in multiple myeloid lineages by serum from patients with SLE or PM/DM using the whole blood stimulation system.

Methods:
Serum was collected from newly diagnosed, untreated, and clinically active adult patients with SLE (SLE group), anti-ARS antibody-positive PM/DM (ARS group), and anti-MDA5 antibody-positive DM (MDA5 group), and healthy controls (HCs) (n=10, respectively). Heparinized whole blood from healthy donors was incubated with control serum (10 v/v%), patient serum (10 v/v%), or IFNs (IFN-α, IFN-β, and IFN-γ) in the presence of protein transport inhibitor cocktail for six hours. Red blood cells were lysed and leucocytes were fixed at a single step. Intracellular staining was performed and expression of 11 cytokines in CD14⁺ monocytes, CD1c⁺ dendritic cells (DCs), and CD123⁺ DCs were analyzed using flow cytometry. For transcriptomic analyses, sorted CD14⁺ monocytes from healthy donor were incubated with control serum, patient serum, or IFN-β for four hours and bulk RNA-sequencing was performed (n=3). To evaluate significance of JAK-STAT pathway, whole blood from healthy donors was pre-incubated with baricitinib, a JAK1/2 inhibitor, stimulated with patient serum for six hours, and analyzed for cytokine expression as described above.

Results: Serum from SLE and MDA5 groups induced significantly higher monocyte chemoattractant protein-1 (MCP1) and interleukin-1 receptor antagonist (IL-1RA) expression in CD14⁺ monocytes compared to HCs (Figure 1). This monocyte cytokine signature was closely resembled that induced by IFN-β stimulation. Serum from ARS group did not induce any significant cytokine expression in CD14⁺ monocytes. No significant cytokine expression was observed in CD1c⁺ DCs and CD123⁺ DCs. Following stimulation with serum from SLE and MDA5 groups, 612 and 462 genes were elevated (fold change >2, p < 0.05 vs HCs), respectively. Among these elevated genes, 383 genes were commonly elevated between SLE group, MDA5 group, and IFN-β (Figure 2). Pathway analysis showed the highest number of gene elevation in IFN-αβ signaling pathway. Multiple ISGs as well as STAT1/2 were significantly elevated. In agreement with transcriptomic analysis, baricitinib significantly abrogated monocyte cytokine signature, MCP1 and IL-1RA expression, induced by serum from SLE and MDA5 groups (p < 0.05).

Conclusion: Serum from patients with clinically active SLE and anti-MDA5 antibody-positive DM induced shared monocyte cytokine signature through type 1 IFN pathway, suggesting contribution of serum factors to ISG signature in the peripheral CD14⁺monocytes. These 'primed' CD14⁺ monocytes by active serum could contribute to pathogenesis in these diseases.

[1] Antonios Psarras, et al. Rheumatology (Oxford). 2017;56(10):1662-1675
Figure 1. MCP1 and IL-1RA expression in CD14+ monocytes following incubation with serum. Whole blood from healthy donors was incubated with patient serum or healthy serum. Expression of each cytokine was analyzed using flow cytometry. Frequencies of CD14+ monocytes positive for MCP1 (panel A) and IL-1RA (panel B) are displayed for SLE group, MDA5 group, ARS group, and HCs (n=10, respectively). Cut-off level was determined by 2% positivity of each cytokine in unstimulated condition. Horizontal bars represent the median. P-values were calculated using Kruskal-Wallis one-way analysis of variance followed by Dunn’s multiple comparisons test.

<img src=https://www.abstractscorecard.com/uploads/Tasks/upload/17574/QHOPTGBB-1288558-2-ANY(1).jpg width=440 height=376.605825242718 border=0 style=border-style: none;>
Disclosures: S. Nakamura, None; Y. okamoto, Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K.; Y. Katsumata, GlaxoSmithKline K.K., AstraZeneca K.K., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., Asahi Kasei Pharma, Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc.; M. Harigai, AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb(BMS), Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Eli Lilly Japan K.K., Kaken Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Ltd., UCB Japan Co., Ltd., Viatris Japan.